Sandison Taylor Form 4 Cidara Therapeutics / Taylor Sandison ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Sandison Taylor

(Last) (First) (Middle)

6310 NANCY RIDGE DR, SUITE 101

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cidara Therapeutics, Inc. [ CDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/18/2019

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$13.62	12/18/2019		D			19,000	(1)	10/29/2025	Common Stock	19,000	(2)	0	D
Employee Stock Option (right to buy)	$2.45	12/18/2019		A		12,667		(3)	12/17/2026	Common Stock	12,667	(2)	12,667	D
Employee Stock Option (right to buy)	$9.89	12/18/2019		D			5,000	(4)	03/15/2026	Common Stock	5,000	(5)	0	D
Employee Stock Option (right to buy)	$2.45	12/18/2019		A		3,333		(3)	12/17/2026	Common Stock	3,333	(5)	3,333	D
Employee Stock Option (right to buy)	$11.11	12/18/2019		D			20,000	(6)	08/31/2026	Common Stock	20,000	(7)	0	D
Employee Stock Option (right to buy)	$2.45	12/18/2019		A		13,333		(3)	12/17/2026	Common Stock	13,333	(7)	13,333	D
Employee Stock Option (right to buy)	$7.8	12/18/2019		D			55,000	(8)	03/30/2027	Common Stock	55,000	(9)	0	D
Employee Stock Option (right to buy)	$2.45	12/18/2019		A		32,592		(3)	12/17/2026	Common Stock	32,592	(9)	32,592	D
Employee Stock Option (right to buy)	$2.45	12/18/2019		A		4,075		(10)	12/17/2026	Common Stock	4,075	(9)	4,075	D

Explanation of Responses:

1. The option provided for vesting as follows: 25% on October 13, 2016 with 1/36th of the remaining shares vesting monthly thereafter, such that all shares subject to the option were vested on October 13, 2019.

2. On December 18, 2019, the issuer canceled, pursuant to the issuer's option exchange program, an option for 19,000 shares of the Issuer's common stock granted to the reporting person on October 30, 2015. In exchange, the reporting person received a replacement option, for 12,667 shares, having an exercise price of $2.45 a share.

3. The option shall vest in full on December 18, 2020.

4. The option provided for vesting in a series of 36 monthly installments and was fully vested on March 16, 2019.

5. On December 18, 2019, the issuer canceled, pursuant to the issuer's option exchange program, an option for 5,000 shares of the Issuer's common stock granted to the reporting person on March 16, 2016. In exchange, the reporting person received a replacement option, for 3,333 shares, having an exercise price of $2.45 a share.

6. The option provided for vesting in a series of 36 monthly installments and was fully vested on September 1, 2019.

7. On December 18, 2019, the issuer canceled, pursuant to the issuer's option exchange program, an option for 20,000 shares of the Issuer's common stock granted to the reporting person on September 1, 2016. In exchange, the reporting person received a replacement option, for 13,333 shares, having an exercise price of $2.45 a share.

8. The option provided for vesting in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 31, 2017 such that the option would have been fully vested on March 31, 2020.

9. On December 18, 2019, the issuer canceled, pursuant to the issuer's option exchange program, an option for 55,000 shares of the Issuer's common stock granted to the reporting person on March 31, 2017. In exchange, the reporting person received two replacement options, for an aggregate of 36,667 shares, having an exercise price of $2.45 a share.

10. The option vests as follows: 1/3rd shall vest on December 18, 2020, and the balance of the shares will vest in twenty-four (24) equal monthly installments thereafter, such that all shares subject to the option shall be fully vested on December 18, 2022.

Remarks:

	/s/ Jessica Oien, Attorney-in-fact	12/20/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.